OMER - Omeros Corporation
19.48 0.00 (0.01%)
After hours: 6:01PM EDT
| Previous Close | 18.99 |
| Open | 18.99 |
| Bid | 19.40 x 800 |
| Ask | 21.00 x 1400 |
| Day's Range | 18.86 - 19.69 |
| 52 Week Range | 8.36 - 27.09 |
| Volume | 491,469 |
| Avg. Volume | 1,357,495 |
| Market Cap | 940.74M |
| Beta | 3.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 36.40 |
- ACCESSWIRE•9 days ago
Breakfast Technical Briefing on Omeros and Three Other Additional Biotech Stocks
Stock Research Monitor: NLNK, OHRP, and ONCS LONDON, UK / ACCESSWIRE / June 12, 2018 / If you want a free Stock Review on OMER sign up now at www.wallstequities.com/registration . On Monday, benchmark ...
- ACCESSWIRE•23 days ago
Wired News – Omeros Settles Lawsuit Against Lupin for Filing ANDA With FDA for Marketing Generic Version of OMIDRIA(R)
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Omeros Corp. (NASDAQ: OMER), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=OMER as the Company's latest news hit the wire. On May 24, 2018, the Company announced that it has reached a settlement agreement with Lupin Ltd and its subsidiary Lupin Pharmaceuticals, Inc. ("Lupin") to resolve the patent infringement lawsuit filed against Lupin. Omeros had filed the case against Lupin as it had filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for approval to market a generic version of Omeros' commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.
- Business Wire•28 days ago
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
Omeros Corporation (OMER) today announced that it has entered into a settlement agreement with Lupin Ltd. and its subsidiary Lupin Pharmaceuticals, Inc. (Lupin), resolving Omeros’ patent litigation against Lupin. The litigation concerned Lupin’s filing of an Abbreviated New Drug Application (ANDA) seeking approval from the U.S. Food and Drug Administration (FDA) to market a generic version of Omeros’ commercial drug OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3%.
- Motley Fool•last month
Why Omeros, Party City Holdco, and Overstock.com Slumped Today
Find out which of these stocks was pressured by cryptocurrency fluctuations.
- Thomson Reuters StreetEvents•last month
Edited Transcript of OMER earnings conference call or presentation 10-May-18 8:30pm GMT
Q1 2018 Omeros Corp Earnings Call
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: Omeros and bluebird bio
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / U.S. markets were mixed on Friday, with the Dow Jones logging its 7th consecutive daily gain, the longest streak since 2017. Comments from President Trump on ...
- Motley Fool•last month
Here's Why Omeros Corporation Stock Is Surging Today
Pipeline progress outlined during the company's first-quarter report lifted spirits.
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Omeros Corporation
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained ...
- Associated Press•last month
Omeros: 1Q Earnings Snapshot
The Seattle-based company said it had a loss of 62 cents per share. Losses, adjusted for non-recurring costs, came to 53 cents per share. The drug developer posted revenue of $1.6 million in the period. ...
- Business Wire•last month
Omeros Corporation Reports First Quarter 2018 Financial Results
Omeros Corporation today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2018, which include:
- Business Wire•last month
Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018
Omeros Corporation (OMER) today announced that the company will issue its first quarter 2018 financial results for the period ended March 31, 2018, on Thursday, May 10, 2018, after the market closes. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results. To access the live and subsequently archived webcast of the conference call, go to Omeros’ website at www.omeros.com and go to “Events” under the Investors section of the website.
- Business Wire•2 months ago
FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
Omeros Corporation (OMER) today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to OMS721 for the treatment of patients with high-risk hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), specifically those patients who have persistent TMA despite modification of immunosuppressive therapy. This is the second breakthrough therapy drug designation for OMS721, which last year received the designation from FDA for the treatment of Immunoglobulin A (IgA) nephropathy.
- GlobeNewswire•2 months ago
Research Report Identifies T. Rowe Price Group, Omeros, Old Dominion Freight Line, Dillard's, BGC Partners, and Rexnord with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, April 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•2 months ago
Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
Omeros Corporation announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018.
- Business Wire•2 months ago
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
Omeros Corporation today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery Congress in Washington, D.C., April 13-17, 2018.
- Business Wire•2 months ago
OMIDRIA® Added to Veterans Health Administration National Formulary
Omeros Corporation today announced that the Veterans Administration has added OMIDRIA® to the VA National Formulary.
- Market Realist•2 months ago
Why Omeros Stock Rose Last Week
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
- Business Wire•2 months ago
Omeros Announces Amendment of Credit Facility
Omeros Corporation today announced that it has entered into an amendment to its existing credit facility with certain affiliates of CRG LP, a healthcare-focused investment firm.
- Simply Wall St.•3 months ago
What Should Investors Know About Omeros Corporation’s (NASDAQ:OMER) Growth?
Omeros Corporation’s (NASDAQ:OMER) announced its latest earnings update in December 2017, which signalled that losses became smaller relative to the prrior year’s level – great news for investors Below, I’veRead More...
- Market Realist•3 months ago
A Look at Omeros’s Promising Research Pipeline
An Investor's Overview of Omeros
- Market Realist•3 months ago
Why Omeros’s Revenue Surged
Omeros (OMER) generated total revenue of $64.8 million in fiscal 2017, compared with $41.6 million in fiscal 2016. Between fiscal 2016 and fiscal 2017, Omeros’s product sale costs fell to $1 million from $1.4 million, and its SG&A (selling, general and administrative expenses) rose to $52 million from $43.7 million.
- Market Realist•3 months ago
Analysts’ Ratings for Omeros and Peers in March 2018
An Investor's Overview of OmerosCompany overview
- Benzinga•3 months ago
Omeros, Mattel, And 3 Other Stocks In Clear Trending Patterns This Week
In light of Monday's volatility, here are five stocks to watch this week according to VantagePoint , a platform that uses artificial intelligence and Intermarket analysis to predict price movement. What's ...
- Benzinga•3 months ago
ICYMI: GameStop, Omeros, Congress Impacts Biotechs
In case you missed it, here are some of Benzinga's top stories from Thursday, March 22, 2018. GameStop’s Turnaround Progress With GameStop Corp (NYSE: GME ) reporting its Q4 results next week, analysts ...
